PharmaCyte Biotech (NASDAQ:PMCB) Posts Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) announced its earnings results on Friday. The company reported ($0.29) earnings per share (EPS) for the quarter, Zacks reports.

PharmaCyte Biotech Stock Performance

NASDAQ:PMCB traded up $0.05 during mid-day trading on Friday, reaching $1.72. The stock had a trading volume of 8,228 shares, compared to its average volume of 23,956. The stock has a market capitalization of $13.21 million, a P/E ratio of 2.62 and a beta of -0.21. The firm has a 50 day moving average price of $1.75 and a two-hundred day moving average price of $1.86. PharmaCyte Biotech has a one year low of $1.39 and a one year high of $2.58.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.